Agios Pharmaceuticals Inc (AGIO)
33.03
+0.09
(+0.27%)
USD |
NASDAQ |
May 10, 16:00
33.03
0.00 (0.00%)
After-Hours: 20:00
Agios Pharmaceuticals Cash from Financing (TTM): 8.83M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 8.83M |
December 31, 2023 | 5.433M |
September 30, 2023 | 4.608M |
June 30, 2023 | 3.913M |
March 31, 2023 | 3.609M |
December 31, 2022 | 2.35M |
September 30, 2022 | -16.26M |
June 30, 2022 | -268.43M |
March 31, 2022 | -771.82M |
December 31, 2021 | -765.77M |
September 30, 2021 | -746.60M |
June 30, 2021 | -492.17M |
March 31, 2021 | 263.39M |
December 31, 2020 | 261.52M |
September 30, 2020 | 538.54M |
June 30, 2020 | 538.43M |
March 31, 2020 | 290.14M |
December 31, 2019 | 289.61M |
September 30, 2019 | 13.02M |
June 30, 2019 | 16.91M |
March 31, 2019 | 22.61M |
December 31, 2018 | 546.02M |
September 30, 2018 | 547.60M |
Date | Value |
---|---|
June 30, 2018 | 545.70M |
March 31, 2018 | 809.34M |
December 31, 2017 | 285.11M |
September 30, 2017 | 286.51M |
June 30, 2017 | 444.42M |
March 31, 2017 | 172.72M |
December 31, 2016 | 169.78M |
September 30, 2016 | 167.07M |
June 30, 2016 | 6.017M |
March 31, 2016 | 5.659M |
December 31, 2015 | 6.373M |
September 30, 2015 | 244.14M |
June 30, 2015 | 242.34M |
March 31, 2015 | 336.40M |
December 31, 2014 | 335.16M |
September 30, 2014 | 95.68M |
June 30, 2014 | 219.54M |
March 31, 2014 | 124.44M |
December 31, 2013 | 123.88M |
September 30, 2013 | 124.36M |
June 30, 2013 | 0.16M |
March 31, 2013 | 0.129M |
December 31, 2012 | 0.142M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-771.82M
Minimum
Mar 2022
538.54M
Maximum
Sep 2020
-41.04M
Average
5.020M
Median
Cash from Financing (TTM) Benchmarks
Alnylam Pharmaceuticals Inc | 154.67M |
Corcept Therapeutics Inc | -149.45M |
Ligand Pharmaceuticals Inc | -46.99M |
Ocular Therapeutix Inc | 169.83M |
Blueprint Medicines Corp | 186.19M |